irinotecan has been researched along with darunavir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jiang, W; Lan, T; Li, D; Ren, Y; Tian, J; Zhang, G; Zhang, X | 1 |
1 review(s) available for irinotecan and darunavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for irinotecan and darunavir
| Article | Year |
|---|---|
Darunavir alleviates irinotecan-induced intestinal toxicity in Vivo.
Topics: Animals; Cytoprotection; Darunavir; Gene Expression Regulation; Glucuronidase; HMGB1 Protein; Intestinal Mucosa; Intestines; Irinotecan; Male; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Occult Blood; Tight Junction Proteins; Toll-Like Receptor 4 | 2018 |